Tetraphase wins $67M BARDA contract; Genzyme vet named CMO at bluebird;

@FierceBiotech: Researchers soup up patients' own immune cells to attack HIV. Story | Follow @FierceBiotech

@JohnCFierce: Fledgling Mnemosyne Pharmaceuticals snags a $5.4 million Series A for neuropsychiatric work. Release | Follow @JohnCFierce

@RyanMFierce: Not for those with arachnophobia: J&J to develop painkillers with spider venom in the mix. Article | Follow @RyanMFierce

@FierceMedDev: Edwards has received CE Mark for its EDWARDS INTUITY for those undergoing surgical aortic valve replacement. Release | Follow @FierceMedDev

> Tetraphase Pharmaceuticals says that the Biomedical Advanced Research and Development Authority (BARDA) has awarded it a contract worth up to $67 million for the development of TP-434, its lead antibiotic. Release

> Cambridge, MA-based bluebird bio has named Dr. David M. Davidson, a Genzyme vet, to the role of chief medical officer. Release

> Curis and Debiopharm say investigators have begun treating patients in a Phase Ib clinical trial of Heat Shock Protein 90 inhibitor Debio 0932. Release

> Germany's Evotec AG and IR Pharma have forged a strategic alliance to offer integrated drug discovery solutions to pharma and biotech companies working in the respiratory disease field. Release

Pharma News

@FiercePharma: Yet another Ben Venue fumble: Sanofi's Genzyme unit recalls leukemia drug made at Ohio plant--Bloomberg. News | Follow @FiercePharma

> Wyeth puts $960M squeeze on Sun for Protonix launch. Article

> Sanofi yanks drug batch on CMO contamination fears. News

> Fake Avastin may not be the only counterfeit on doctors' shelves. More

Manufacturing News

> Hospira sees dim light at end of plant troubles. Piece

> FDA inspects three Merck KGaA plants along EU supply chain. Item

> West-Ward hit with warning letter over manufacturing, testing problems. Article

> U.S. market size, shortages lead to more counterfeits. Story

CRO News

> Complete Genomics soars after it snags sequencing deal with Mayo Clinic. Story

> Charles River sees signs of growth in latest assessment. More

> Quintiles to offer guidance on navigating Asian drug projects. News

> Ockham adds international oncology CRO ops in Nexus buyout. Article

> Report: Catalent wants $400M loan to back Aptuit unit buyout. Item

Vaccines News

> FDA says no to Novartis' Menveo vax for babies. Article

> Gynecological cancer vaccine enters clinical trials. More

> Research paving way to salmonella vaccine. Story

> IIL developing firsts for vaccines in India. News

> Sanofi's Shantha Biotechnics hopes to relaunch vaccine. Item

And Finally... New research by Rice University and the University of Texas MD Anderson Cancer Center indicates that a combination of drugs and carbon nanoparticles may enhance treatment for head-and-neck cancers, especially when combined with radiation therapy. Release

Suggested Articles

As Relay looks to enter the clinic in 2020, the company is adding a trio of biopharma vets to its leadership team.

A phase 3 trial of Myovant Sciences’ relugolix in prostate cancer has met its primary endpoint, teeing the company up to file for FDA approval.

The Medicines Company, fresh from its turn at the AHA this weekend, has seen its shares jump on growing rumors that Novartis wants to acquire it.